Casey McPherson Casey McPherson

Investor Update

05.12.25

When I started AlphaRose Therapeutics I knew we needed a company to create a new business model for genetic diseases and we embarked on our mission with conviction and determination on behalf of my daughter, Rose, and the millions of other children and adults out there affected by an ultra rare disease.

AlphaRose is at the forefront of technological advancement, poised for significant growth as well as patient and market impact. I have found, however, that the speed at which we accomplish all of this is dependent on fundraising. 

It has been incredible to see investors, biotech executives, and scientists embrace our mission focused on precision genetic medicine! I am bullish on FDA regulatory changes with this administration, making a new business model like AlphaRose even better than we currently project. 

I want to first thank our current investors and your belief in our ability to change lives, and also to those interested in our journey. Below are some updates on the company, and a reminder that our current Seed Round offering price is projected to close on June 18th.  With our recent acquisition of Alpha Anomeric, a platform ASO technology, we expect our valuation to significantly increase post our seed round.

Press and Event Highlights

  • Presented at the Biotech Summit in San Francisco, garnering significant interest from industry leaders.

  • AlphaRose to be featured in Rare Magazine’s biotech issue 

  • Interviews from Fox (San Diego), NBC (San Francisco), NBC Austin on AlphaRose

  • Presented at Capital Factory’s “First Look,” garnering significant investor interest 

  • KXAN Interview (going national) 

  • Presented at University of Texas / Dell Medical School

  • Invited to speak at Capital Factory’s Health SuperNova on June 12th in Austin, Texas

  • Presenting at the BIO International Convention mid-June in Boston 

The slide that seemed to connect with the widest audience. Genetic treatments like our technology target the underlying cause of disease, which has shown to increase success rates exponentially.

Fundraising Updates

We’ve raised $1.2M in our Reg CF financing that started in Feb 2025, for our active Seed Round (www.startengine.com/alpharose) 

  • Currently in discussions with multiple investors 

  • CF Round closing projected for June 18th, 2025

AlphaRose Milestones and Updates

  • Rosiphersen -  Our preclinical safety study was a resounding success! The data indicate a strong safety profile and we are now planning for formal IND-enabling safety studies.

  • ClinOps/Regulatory Team - We’ve established a team to move Rosiphersen into the clinic as well as to write the IND. 

  • Pipeline - Utilizing our ARGUS AI platform we’ve identified 20 initial candidate diseases for which we can design proprietary ASO therapies, and we are starting laboratory work on the first new treatments this quarter (Q2 2025)

  • Acquisition of a proprietary ASO Chemistry Platform Company - We have acquired the French company, Alpha Anomeric SA with a new technology that we are extremely excited about implementing into our platform. This ASO chemistry has the potential to be safer in humans, bring us big pharma partnership opportunities, as well as providing us a more highly protected platform for differentiation. 

Q2-Q4 CY2025 Milestones

  • Q2: Estimated closing of our Seed Round, projected June 18th, 2025. 

  • Q3: AI Design tool for ASOs (Sentinel) V1 is complete, to be tested in Q3 2025. 

  • Q3: Early data on new potential treatments in Q3 2025.

  • Q3/4: Initiation of IND enabling studies for Rosiphersen, with anticipated data readout as early as Q4 2025.

How you can participate:

Become an investor yourself as well as introduce us to potential investors for whom our mission will resonate. This company is being built by thought leaders and mission driven investors that want to change the system for the millions of rare and ultra rare children that will never see a treatment unless we do.


Please feel free to set up a call if you have any questions, or you would like to discuss additional investment opportunities with the company. We would love for you to join us on this journey! 

Calendly: Book here

Patients are waiting, 

Casey McPherson

CEO - AlphaRose Therapeutics

This investor update is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of AlphaRose Therapeutics. Any offer or solicitation will be made only through a definitive offering document and in compliance with applicable securities laws.Investing in AlphaRose Therapeutics involves a high degree of risk, including the potential loss of your entire investment. This investment is speculative, illiquid, and may not be suitable for all investors. Past performance is not indicative of future results.Specifically, the Regulation CF offering mentioned in this update is made available through StartEngine Primary, LLC. This is a speculative investment that involves significant risks, including illiquidity and the possibility of loss of principal. Investors should carefully review the offering materials at www.startengine.com/alpharose before making an investment decision.Forward-looking statements are based on current expectations and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially. We undertake no obligation to update or revise any forward-looking statements. Potential investors are strongly advised to consult with their own legal, tax, and financial advisors before making any investment.

Read More